REUTERS - Pfizer Inc reported a bigger-than-expected quarterly profit, benefiting from strong demand for its newer drugs.
Shares of the largest U.S. drugmaker were up 1.7 percent in premarket trade on Tuesday.
Pfizer's net income rose to $2.84 billion, or 47 cents per share, in the third quarter, from $1.36 billion, or 22 cents per share, a year earlier.
Excluding one-time items, Pfizer earned 67 cents per share in the quarter, above the average analysts' estimate of 64 cents per share, according to Thomson Reuters I/B/E/S.
Revenue rose to $13.17 billion from $13.05 billion. Sales of Pfizer's breast cancer treatment, Ibrance, surged nearly 60 percent to $878 million.
(Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Saumyadeb Chakrabarty and Savio D'Souza)
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app